To identify possible protein markers for a disease, mass spectrometry-based proteomics remains a key technology. Clinical specimens that are typically used amongst others include liquid biopsies (e.g., blood plasma and CSF). My lab is involved in a multi-center project that aims at identifying novel protein biomarkers for frontotemporal degeneration. To help us, we will hire a researcher who will prepare samples for analysis by mass spectrometry, assists the mass spectrometric analyses, and analyses and interprets the data obtained.
For more information, pleasr refer to the VIB website by clicking the image below.